Image For Activity Cover
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial (JACC Heart Failure August 2021)

In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of CV death or hospitalization for heart failure (HHF) by 34% in subjects with T2D and CV disease. Among such subjects, there has been limited evaluation of clinical phenotypes. 


Christopher O’Connor, MD, FACC

Executive Editor
Mona Fiuzat, PharmD, FACC

JACC Heart Failure CME Editors
Tariq Ahmad, MD, MPH
Adam DeVore, MD
Abhinav Sharma, MD
Mitchell Psotka, MD, PhD
Kishan Parikh, MD


Abhinav Sharma, MD, PHD 
Anne Pernille Ofstad, MD, PHD
Robert J. Mentz, MD

Important Dates

Date of Release: July 29, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: July 28, 2022

Availability: On-Demand
Expires on Jul 28, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By